Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
BACKGROUND
Prediction of optimal cytoreduction in patients with advanced epithelial ovarian caner preoperatively.


METHODS
Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan. to June 2008 at gynecologic oncology ward of TUMS (Tehran University of Medical Sciences) were eligible for this study. The possibility of predicting primary optimal cytoreduction considering multiple variables was evaluated. Variables were peritoneal carcinomatosis, serum CA125, ascites, pleural effusion, physical status and imaging findings.Univariate comparisons of patients underwent suboptimal cytoreduction carried out using Fisher's exact test for each of the potential predictors. The wilcoxon rank sum test was used to compare variables between patients with optimal versus suboptimal cytoreduction.


RESULTS
41 patients met study inclusion criteria. Statistically significant association was noted between peritoneal carcinomatosis and suboptimal cytoreduction. There were no statistically significant differences between physical status, pleural effusion, imaging findings, serum CA125 and ascites of individuals with optimal cytoreduction compared to those with suboptimal cytoreduction.


CONCLUSIONS
Because of small populations in our study the results are not reproducible in alternate populations. Only the patient who is most unlikely to undergo optimal cytoreduction should be offered neoadjuvant chemotherapy, unless her medical condition renders her unsuitable for primary surgery.
Mousavi
Azam-Sadat
AS
Department of Gynecology Oncology, vali-e-asr hospital, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, 1419733141, Iran.
Mazhari
Marjan Moradi
MM
Guilani
Mitra Modares
MM
Ghaemmaghami
Fatemeh
F
Behtash
Nadereh
N
Akhavan
Setareh
S
D001201:Ascites; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000473:pathology* / Q000601:surgery; D010996:Pleural Effusion; D011300:Preoperative Care; D011379:Prognosis; D011446:Prospective Studies
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen